{
    "hands_on_practices": [
        {
            "introduction": "Effective clinical practice hinges on the judicious use and correct interpretation of diagnostic tests. The performance of a test, particularly in a screening context, is not solely determined by its intrinsic sensitivity and specificity but is profoundly influenced by the pre-test probability of the disease in the population. This exercise  provides a critical, hands-on application of Bayes' theorem to calculate the Positive Predictive Value ($PPV$) of a rubella IgM assay, illustrating why a high proportion of positive results can be false in low-prevalence settings and underscoring the need for confirmatory testing.",
            "id": "5168957",
            "problem": "A pediatric public health program is evaluating the suitability of population screening for acute rubella using a serum Immunoglobulin M (IgM) assay among children during a non-outbreak period. Assume that the point prevalence of true acute rubella infection is $0.5\\%$. The assay has sensitivity $95\\%$ and specificity $98\\%$. Positive predictive value (PPV) is defined as the posterior probability that infection is present given a positive test.\n\nStarting only from the definitions of sensitivity, specificity, prevalence, conditional probability, and the law of total probability, derive an expression for PPV in terms of prevalence, sensitivity, and specificity without invoking any pre-memorized screening-test formulas. Then compute the PPV for the above parameters and report it as a decimal. Round your numerical answer to four significant figures. Do not include a percentage sign in your final numerical answer.\n\nFinally, based on your derivation, briefly justify whether stand-alone IgM screening for rubella in asymptomatic children in low-prevalence settings is likely to generate a high or low proportion of false positives, and why this matters for confirmatory testing in pediatrics. Your justification should be grounded in your probabilistic derivation rather than heuristic statements.",
            "solution": "The problem statement is evaluated for validity.\n\n**Step 1: Extract Givens**\n- Point prevalence of true acute rubella infection: $0.5\\%$\n- Assay sensitivity: $95\\%$\n- Assay specificity: $98\\%$\n- Definition of Positive Predictive Value (PPV): The posterior probability that infection is present given a positive test.\n- The derivation must start from the definitions of sensitivity, specificity, prevalence, conditional probability, and the law of total probability.\n- The final numerical answer for PPV must be reported as a decimal rounded to four significant figures.\n- A justification is required regarding the proportion of false positives in low-prevalence settings, grounded in the derived formula.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, using standard definitions from epidemiology and probability theory (prevalence, sensitivity, specificity, conditional probability). The numerical values are realistic for a diagnostic assay. The problem is well-posed, providing all necessary information to derive the formula and compute the value. It is objective and free of ambiguity. The problem requests a first-principles derivation, which is a standard and valid task in a scientific or mathematical context. No flaws are identified.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A complete solution will be provided.\n\n**Derivation of the Positive Predictive Value (PPV)**\n\nLet us define the following events:\n- $D$: The event that a child has the disease (true acute rubella infection).\n- $D^c$: The event that a child does not have the disease.\n- $T^+$: The event that the assay result is positive.\n- $T^-$: The event that the assay result is negative.\n\nThe givens can be formally expressed as probabilities:\n- Prevalence, $P(D) = 0.5\\% = 0.005$.\n- Sensitivity, the probability of a positive test given the disease is present, is $P(T^+|D) = 95\\% = 0.95$.\n- Specificity, the probability of a negative test given the disease is absent, is $P(T^-|D^c) = 98\\% = 0.98$.\n\nFrom these, we can deduce two other necessary probabilities:\n- The probability of not having the disease is $P(D^c) = 1 - P(D) = 1 - 0.005 = 0.995$.\n- The probability of a positive test given the disease is absent (the false positive rate) is the complement of the specificity: $P(T^+|D^c) = 1 - P(T^-|D^c) = 1 - 0.98 = 0.02$.\n\nThe Positive Predictive Value (PPV) is defined as the posterior probability that the disease is present given a positive test result, which is denoted by the conditional probability $P(D|T^+)$.\n\nUsing the definition of conditional probability:\n$$ \\text{PPV} = P(D|T^+) = \\frac{P(D \\cap T^+)}{P(T^+)} $$\n\nThe numerator, $P(D \\cap T^+)$, is the probability of having the disease and testing positive. From the definition of conditional probability for sensitivity, $P(T^+|D) = \\frac{P(D \\cap T^+)}{P(D)}$, we can rearrange to find the numerator:\n$$ P(D \\cap T^+) = P(T^+|D) \\times P(D) $$\n\nThe denominator, $P(T^+)$, is the total probability of obtaining a positive test result. We can expand this using the law of total probability. A positive test can occur in two mutually exclusive scenarios: (1) the person has the disease and tests positive, or (2) the person does not have the disease and tests positive.\n$$ P(T^+) = P(D \\cap T^+) + P(D^c \\cap T^+) $$\nUsing the definition of conditional probability for each term:\n$$ P(T^+) = (P(T^+|D) \\times P(D)) + (P(T^+|D^c) \\times P(D^c)) $$\n\nNow, we substitute the expanded expressions for the numerator and the denominator back into the PPV equation:\n$$ \\text{PPV} = P(D|T^+) = \\frac{P(T^+|D) \\times P(D)}{(P(T^+|D) \\times P(D)) + (P(T^+|D^c) \\times P(D^c))} $$\nThis is the expression for PPV derived from first principles. Let us denote prevalence as $p$, sensitivity as $s_e$, and specificity as $s_p$. The expression becomes:\n$$ \\text{PPV} = \\frac{s_e \\times p}{(s_e \\times p) + ((1 - s_p) \\times (1 - p))} $$\n\n**Calculation of PPV**\n\nNow we substitute the given numerical values into the derived formula:\n- $p = P(D) = 0.005$\n- $s_e = P(T^+|D) = 0.95$\n- $s_p = P(T^-|D^c) = 0.98$, which implies $P(T^+|D^c) = 1 - 0.98 = 0.02$.\n- $1 - p = P(D^c) = 0.995$.\n\nThe numerator represents the probability of a true positive result:\n$$ P(T^+|D) \\times P(D) = 0.95 \\times 0.005 = 0.00475 $$\n\nThe denominator consists of the probability of a true positive result plus the probability of a false positive result:\n$$ (P(T^+|D) \\times P(D)) + (P(T^+|D^c) \\times P(D^c)) = (0.95 \\times 0.005) + (0.02 \\times 0.995) $$\n$$ = 0.00475 + 0.0199 = 0.02465 $$\n\nTherefore, the PPV is:\n$$ \\text{PPV} = \\frac{0.00475}{0.02465} \\approx 0.19269776876... $$\n\nRounding to four significant figures, we get:\n$$ \\text{PPV} \\approx 0.1927 $$\n\n**Justification on False Positives**\n\nThe derivation provides the means to analyze the composition of positive test results. The denominator of the PPV formula, $P(T^+) = (s_e \\times p) + ((1 - s_p) \\times (1 - p))$, is the sum of the probabilities of all positive results.\n- The term $s_e \\times p$ represents the proportion of true positives in the total population.\n- The term $(1 - s_p) \\times (1 - p)$ represents the proportion of false positives in the total population.\n\nIn low-prevalence settings, the prevalence $p$ is a very small number. Consequently:\n1.  The true positive term, $s_e \\times p$, becomes very small because it is a product containing the small term $p$. In our case, this is $0.95 \\times 0.005 = 0.00475$.\n2.  The false positive term, $(1 - s_p) \\times (1 - p)$, is the product of the false positive rate $(1 - s_p)$ and the proportion of the population without the disease $(1 - p)$. Since $p$ is small, $(1 - p)$ is close to $1$. Therefore, this term is primarily determined by the false positive rate $(1-s_p)$. In our case, this is $0.02 \\times 0.995 = 0.0199$.\n\nThe ratio of false positives to true positives is $\\frac{(1 - s_p)(1 - p)}{s_e p} = \\frac{0.0199}{0.00475} \\approx 4.19$. This shows that for every single true positive result, there are more than four false positive results.\n\nThis demonstrates that stand-alone IgM screening in a low-prevalence setting will generate a high proportion of false positives. The vast majority of positive test results (approximately $1 - 0.1927 = 0.8073$, or $80.73\\%$) do not indicate a true infection. This matters critically in pediatrics because a false positive diagnosis can cause significant parental anxiety, lead to unnecessary follow-up procedures, and potentially result in incorrect public health actions or medical advice. Therefore, any positive result from such a screening program is highly suspect and must be confirmed with a more specific diagnostic method (such as serological testing of paired sera) before a definitive diagnosis is made.",
            "answer": "$$\n\\boxed{0.1927}\n$$"
        },
        {
            "introduction": "When a highly contagious disease like measles emerges, swift and targeted public health action is crucial to prevent widespread transmission. Ring vaccination, the rapid immunization of close contacts of a confirmed case, is a cornerstone of outbreak control. This practice problem  allows you to move from diagnostic theory to practical intervention by quantifying the direct impact of a post-exposure prophylaxis campaign. By calculating the expected absolute reduction in the Secondary Attack Rate ($SAR$), you will develop a quantitative understanding of how vaccination coverage and effectiveness translate into tangible disease prevention within a high-risk group.",
            "id": "5168955",
            "problem": "A measles outbreak occurs in a primary school. Consider a single, well-defined classroom contact network in which the baseline secondary attack rate (Secondary Attack Rate (SAR)) in the absence of intervention is $50\\%$. Within $72$ hours of rash onset in the index case, a ring vaccination campaign is implemented targeting all susceptible classroom contacts. Of those eligible, $85\\%$ accept vaccination, and the measles-containing vaccine administered within $72$ hours has an effectiveness of $93\\%$ at preventing clinical measles among vaccinated contacts in this context.\n\nUsing only the definitions that (i) SAR is the risk of disease among contacts over the outbreak period, (ii) vaccine effectiveness is the proportional reduction in disease risk among vaccinated compared with unvaccinated under comparable exposure, and assuming that over the short time horizon there are no indirect (herd) effects beyond the direct protection of vaccinated individuals, independence of individual-level risks, and no change in susceptibility among unvaccinated contacts, calculate the expected absolute reduction in the classroom SAR attributable to the ring vaccination campaign relative to the baseline. Round your answer to four significant figures. Express your final answer as a decimal fraction with no percent sign.",
            "solution": "The problem will be validated before a solution is attempted.\n\n### Step 1: Extract Givens\nThe explicit data, definitions, and conditions provided in the problem statement are:\n-   Baseline Secondary Attack Rate ($SAR_{baseline}$): $50\\%$\n-   Time window for intervention: within $72$ hours of rash onset\n-   Vaccination coverage of eligible contacts ($C$): $85\\%$\n-   Vaccine effectiveness ($VE$): $93\\%$\n-   Definition (i): SAR is the risk of disease among contacts over the outbreak period.\n-   Definition (ii): Vaccine effectiveness is the proportional reduction in disease risk among vaccinated compared with unvaccinated under comparable exposure.\n-   Assumption 1: No indirect (herd) effects beyond the direct protection of vaccinated individuals.\n-   Assumption 2: Independence of individual-level risks.\n-   Assumption 3: No change in susceptibility among unvaccinated contacts.\n-   Objective: Calculate the expected absolute reduction in the classroom SAR.\n-   Precision: Round the final answer to four significant figures.\n-   Format: Express the answer as a decimal fraction.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated against the established validation criteria.\n\n-   **Scientifically Grounded**: The problem is grounded in fundamental principles of epidemiology. Concepts such as Secondary Attack Rate (SAR), vaccine effectiveness (VE), and ring vaccination are standard in infectious disease epidemiology. The provided values for the infectivity of measles ($SAR_{baseline}$ of $50\\%$ in a classroom) and the post-exposure prophylactic effectiveness of the measles vaccine ($VE$ of $93\\%$) are scientifically plausible.\n-   **Well-Posed**: The problem is well-posed. It provides all necessary quantitative data and qualitative assumptions required to calculate a unique solution. The definitions of SAR and VE are explicit and standard, removing ambiguity. The assumptions (e.g., no herd effects, independence of risks) serve to create a clearly defined and solvable mathematical model.\n-   **Objective**: The problem is stated in precise, objective language, free of subjective or opinion-based claims.\n\nThe problem does not exhibit any of the defined flaws. It is scientifically sound, formally structured, internally consistent, and requires a logical application of the provided definitions to arrive at a solution.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. A solution will now be derived.\n\n### Solution Derivation\nLet $SAR_{0}$ denote the baseline secondary attack rate in the absence of intervention. From the problem statement, $SAR_{0} = 50\\% = 0.50$.\nLet $C$ denote the proportion of susceptible contacts who are vaccinated, which is the vaccination coverage. From the problem statement, $C = 85\\% = 0.85$.\nThe proportion of susceptible contacts who remain unvaccinated is therefore $1 - C = 1 - 0.85 = 0.15$.\nLet $VE$ be the vaccine effectiveness, given as $VE = 93\\% = 0.93$.\n\nThe problem provides a precise definition for vaccine effectiveness: the proportional reduction in disease risk among the vaccinated compared with the unvaccinated. Let $R_{v}$ be the risk (i.e., attack rate) among vaccinated contacts, and let $R_{uv}$ be the risk among unvaccinated contacts. The definition of $VE$ can be expressed mathematically as:\n$$\nVE = \\frac{R_{uv} - R_{v}}{R_{uv}} = 1 - \\frac{R_{v}}{R_{uv}}\n$$\nThe problem states to assume \"no change in susceptibility among unvaccinated contacts.\" This implies that the risk for an unvaccinated contact under the intervention scenario is identical to the risk for any contact in the baseline scenario. Thus, we have:\n$$\nR_{uv} = SAR_{0}\n$$\nUsing this, we can now express the risk for vaccinated contacts, $R_{v}$, in terms of $SAR_{0}$ and $VE$. Rearranging the $VE$ formula:\n$$\nR_{v} = R_{uv} (1 - VE) = SAR_{0} (1 - VE)\n$$\nThe new, overall secondary attack rate in the classroom, denoted as $SAR_{new}$, is the weighted average of the risks in the vaccinated and unvaccinated subgroups. The weights are the proportions of the population in each group.\n$$\nSAR_{new} = (C \\times R_{v}) + ((1 - C) \\times R_{uv})\n$$\nSubstituting the expressions for $R_{v}$ and $R_{uv}$:\n$$\nSAR_{new} = (C \\times [SAR_{0} (1 - VE)]) + ((1 - C) \\times SAR_{0})\n$$\nWe can factor out $SAR_{0}$:\n$$\nSAR_{new} = SAR_{0} [C(1 - VE) + (1 - C)]\n$$\nSimplifying the expression inside the brackets:\n$$\nSAR_{new} = SAR_{0} [C - C \\cdot VE + 1 - C]\n$$\n$$\nSAR_{new} = SAR_{0} (1 - C \\cdot VE)\n$$\nThe problem asks for the absolute reduction in the classroom SAR, which we will denote as $\\Delta SAR_{abs}$. This is the difference between the baseline SAR and the new SAR.\n$$\n\\Delta SAR_{abs} = SAR_{0} - SAR_{new}\n$$\nSubstituting the expression for $SAR_{new}$:\n$$\n\\Delta SAR_{abs} = SAR_{0} - SAR_{0} (1 - C \\cdot VE)\n$$\n$$\n\\Delta SAR_{abs} = SAR_{0} [1 - (1 - C \\cdot VE)]\n$$\n$$\n\\Delta SAR_{abs} = SAR_{0} (C \\cdot VE)\n$$\nThis final expression is elegant: the absolute reduction in risk is the baseline risk multiplied by the proportion of the population that is effectively protected (i.e., the coverage multiplied by the effectiveness).\n\nNow, we substitute the given numerical values into this expression:\n$SAR_{0} = 0.50$\n$C = 0.85$\n$VE = 0.93$\n\n$$\n\\Delta SAR_{abs} = 0.50 \\times (0.85 \\times 0.93)\n$$\nFirst, calculate the product inside the parentheses:\n$$\n0.85 \\times 0.93 = 0.7905\n$$\nThen, multiply by the baseline SAR:\n$$\n\\Delta SAR_{abs} = 0.50 \\times 0.7905 = 0.39525\n$$\nThe problem requires the answer to be rounded to four significant figures. The number is $0.39525$. The first four significant figures are $3$, $9$, $5$, and $2$. The fifth significant figure is $5$, which requires rounding up the fourth digit.\n$$\n\\Delta SAR_{abs} \\approx 0.3953\n$$\nThe expected absolute reduction in the classroom SAR is $0.3953$.",
            "answer": "$$ \\boxed{0.3953} $$"
        },
        {
            "introduction": "While outbreak response is vital, the ultimate goal of public health is proactive, long-term disease prevention through robust immunization programs. Achieving and maintaining herd immunity depends on strategic policy decisions that extend beyond individual protection. This final exercise  broadens the scope to the population level, challenging you to model and compare the effectiveness of two different city-wide measles vaccination strategies. By calculating the effective reproduction number, $R_e$, for each scenario, you will mathematically demonstrate the profound public health advantage of a two-dose MMR schedule in suppressing measles transmission.",
            "id": "5169009",
            "problem": "A city with homogeneous mixing is evaluating two measles vaccination program scenarios for children by age $5$. Assume the basic reproduction number $R_0$ for measles is $15$, there is no prior immunity except through vaccination, and protection is determined by seroconversion following vaccination. The measles-mumps-rubella (MMR) vaccine yields individual seroconversion probabilities (vaccine efficacies) of $e_1 = 0.93$ after $1$ dose and $e_2 = 0.97$ after $2$ doses.\n\nScenario A: By age $5$, exactly $90\\%$ receive $1$ MMR dose, $0\\%$ receive $2$ doses, and the remainder are unvaccinated.\n\nScenario B: By age $5$, exactly $15\\%$ receive $1$ MMR dose, $80\\%$ receive $2$ doses, and the remainder are unvaccinated.\n\nAssume a susceptible-infectious-removed (SIR) framework with homogeneous mixing, and that herd effects arise solely from the reduction in the effective susceptible fraction implied by vaccination-induced seroconversion. Using these assumptions, compute the ratio of the effective reproduction numbers $R_{e,A} / R_{e,B}$ for Scenario A relative to Scenario B. Express your final answer as a dimensionless ratio rounded to four significant figures.",
            "solution": "The problem will first be validated for scientific soundness, self-consistency, and well-posedness.\n\n### Step 1: Extract Givens\nThe data and conditions explicitly provided in the problem statement are:\n- Basic reproduction number for measles: $R_0 = 15$.\n- Population: A city with homogeneous mixing.\n- Target cohort: Children by age $5$.\n- Immunity: No prior immunity except through vaccination.\n- Vaccine efficacy (seroconversion probability), $1$ dose: $e_1 = 0.93$.\n- Vaccine efficacy (seroconversion probability), $2$ doses: $e_2 = 0.97$.\n- Scenario A:\n    - Fraction receiving $1$ dose: $c_{1,A} = 90\\% = 0.90$.\n    - Fraction receiving $2$ doses: $c_{2,A} = 0\\% = 0.00$.\n    - Remainder are unvaccinated.\n- Scenario B:\n    - Fraction receiving $1$ dose: $c_{1,B} = 15\\% = 0.15$.\n    - Fraction receiving $2$ doses: $c_{2,B} = 80\\% = 0.80$.\n    - Remainder are unvaccinated.\n- Modeling framework: Susceptible-Infectious-Removed (SIR) model with homogeneous mixing.\n- Herd effects source: Reduction in the effective susceptible fraction due to vaccination-induced seroconversion.\n- Required output: The ratio of the effective reproduction numbers, $R_{e,A} / R_{e,B}$, rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is assessed against the validation criteria.\n1.  **Scientifically Grounded**: The problem uses standard concepts from epidemiology, including the basic reproduction number ($R_0$), effective reproduction number ($R_e$), vaccine efficacy, and the SIR model framework. The value of $R_0 = 15$ for measles is a well-established estimate. The vaccine efficacies for the MMR vaccine are realistic. The model assumptions (homogeneous mixing, immunity via seroconversion) are standard simplifications used in epidemiological modeling. The problem is scientifically sound.\n2.  **Well-Posed**: The problem provides all necessary parameters ($R_0$, vaccine efficacies, and population coverage for two distinct scenarios) to calculate the effective reproduction number in each case and, subsequently, their ratio. The question is unambiguous and has a unique, computable solution.\n3.  **Objective**: The problem is stated in precise, quantitative terms, free from subjective or opinion-based language.\n\nThe problem does not exhibit any flaws such as scientific unsoundness, incompleteness, contradiction, or ambiguity. It is a well-defined quantitative problem in public health modeling.\n\n### Step 3: Verdict and Action\nThe problem is valid. A detailed solution will be provided.\n\nThe effective reproduction number, $R_e$, is defined as the average number of secondary cases produced by a typical infectious individual in a population that is not entirely susceptible. It is related to the basic reproduction number, $R_0$, and the fraction of the population that is susceptible, $s$, by the equation:\n$$R_e = R_0 \\times s$$\nThe core of the problem is to determine the susceptible fraction, $s$, for each scenario. The population is partitioned into three groups: unvaccinated (fraction $c_0$), received $1$ dose (fraction $c_1$), and received $2$ doses (fraction $c_2$).\n\nThe fraction of individuals who remain susceptible after vaccination depends on the vaccine efficacy.\n- For an individual who receives $1$ dose, the probability of becoming immune (seroconverting) is $e_1$. The probability of remaining susceptible is $1 - e_1$.\n- For an individual who receives $2$ doses, the probability of becoming immune is $e_2$. The probability of remaining susceptible is $1 - e_2$.\n- Unvaccinated individuals are all susceptible, so their probability of being susceptible is $1$.\n\nThe total susceptible fraction of the population, $s$, is the weighted average of the susceptibility of each group:\n$$s = c_0 \\cdot (1) + c_1 \\cdot (1 - e_1) + c_2 \\cdot (1 - e_2)$$\n\nWe will now calculate the susceptible fraction for each scenario.\n\n**Scenario A:**\nThe vaccination coverage is given as $c_{1,A} = 0.90$ and $c_{2,A} = 0.00$. The fraction of unvaccinated children is the remainder:\n$$c_{0,A} = 1 - c_{1,A} - c_{2,A} = 1 - 0.90 - 0.00 = 0.10$$\nThe susceptible fraction for Scenario A, $s_A$, is:\n$$s_A = c_{0,A} + c_{1,A}(1 - e_1) + c_{2,A}(1 - e_2)$$\nSubstituting the given values:\n$$s_A = 0.10 + 0.90(1 - 0.93) + 0.00(1 - 0.97)$$\n$$s_A = 0.10 + 0.90(0.07) + 0$$\n$$s_A = 0.10 + 0.063 = 0.163$$\nThe effective reproduction number for Scenario A is $R_{e,A} = R_0 \\times s_A = 15 \\times 0.163$.\n\n**Scenario B:**\nThe vaccination coverage is given as $c_{1,B} = 0.15$ and $c_{2,B} = 0.80$. The fraction of unvaccinated children is:\n$$c_{0,B} = 1 - c_{1,B} - c_{2,B} = 1 - 0.15 - 0.80 = 0.05$$\nThe susceptible fraction for Scenario B, $s_B$, is:\n$$s_B = c_{0,B} + c_{1,B}(1 - e_1) + c_{2,B}(1 - e_2)$$\nSubstituting the given values:\n$$s_B = 0.05 + 0.15(1 - 0.93) + 0.80(1 - 0.97)$$\n$$s_B = 0.05 + 0.15(0.07) + 0.80(0.03)$$\n$$s_B = 0.05 + 0.0105 + 0.024$$\n$$s_B = 0.0845$$\nThe effective reproduction number for Scenario B is $R_{e,B} = R_0 \\times s_B = 15 \\times 0.0845$.\n\n**Ratio of Effective Reproduction Numbers:**\nThe problem asks for the ratio $R_{e,A} / R_{e,B}$.\n$$\\frac{R_{e,A}}{R_{e,B}} = \\frac{R_0 \\times s_A}{R_0 \\times s_B} = \\frac{s_A}{s_B}$$\nThe basic reproduction number $R_0$ cancels out. We substitute the calculated values for $s_A$ and $s_B$:\n$$\\frac{R_{e,A}}{R_{e,B}} = \\frac{0.163}{0.0845}$$\nPerforming the division:\n$$\\frac{0.163}{0.0845} \\approx 1.92899408284...$$\nThe problem requires the answer to be rounded to four significant figures.\n$$1.929$$\nThus, the effective reproduction number in Scenario A is approximately $1.929$ times that in Scenario B. This demonstrates the superior herd immunity effect of the two-dose strategy (Scenario B) despite slightly lower overall coverage ($95\\%$ vs $90\\%$). The higher efficacy of the second dose is critical.",
            "answer": "$$\\boxed{1.929}$$"
        }
    ]
}